WO2007113005A3 - 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors - Google Patents

2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors Download PDF

Info

Publication number
WO2007113005A3
WO2007113005A3 PCT/EP2007/003011 EP2007003011W WO2007113005A3 WO 2007113005 A3 WO2007113005 A3 WO 2007113005A3 EP 2007003011 W EP2007003011 W EP 2007003011W WO 2007113005 A3 WO2007113005 A3 WO 2007113005A3
Authority
WO
WIPO (PCT)
Prior art keywords
aurora kinase
aminosulfonyl
substituted
kinase inhibitors
thiophene derivatives
Prior art date
Application number
PCT/EP2007/003011
Other languages
French (fr)
Other versions
WO2007113005A2 (en
Inventor
Joe Lewis
Elena Conti
Arulanandam Arocki Jeyaprakash
Original Assignee
European Molecular Biology Lab Embl
Joe Lewis
Elena Conti
Arulanandam Arocki Jeyaprakash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by European Molecular Biology Lab Embl, Joe Lewis, Elena Conti, Arulanandam Arocki Jeyaprakash filed Critical European Molecular Biology Lab Embl
Publication of WO2007113005A2 publication Critical patent/WO2007113005A2/en
Publication of WO2007113005A3 publication Critical patent/WO2007113005A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel compounds that inhibit cell proliferation, in particular by inhibiting Aurora kinase activity and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition of Aurora kinase activity, in particular hyperproliferative diseases.
PCT/EP2007/003011 2006-04-03 2007-04-03 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors WO2007113005A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2006/003018 2006-04-03
EP2006003018 2006-04-03

Publications (2)

Publication Number Publication Date
WO2007113005A2 WO2007113005A2 (en) 2007-10-11
WO2007113005A3 true WO2007113005A3 (en) 2008-01-03

Family

ID=37611414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/003011 WO2007113005A2 (en) 2006-04-03 2007-04-03 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2007113005A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560636A4 (en) * 2010-04-23 2013-11-27 Kineta Inc Anti-viral compounds

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000649A1 (en) * 2000-06-28 2002-01-03 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
WO2003022852A2 (en) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US20030187001A1 (en) * 1997-03-19 2003-10-02 David Calderwood 4-aminopyrrolopyrimidines as kinase inhibitors
US20040097531A1 (en) * 2002-07-09 2004-05-20 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
WO2004069139A2 (en) * 2003-02-10 2004-08-19 F.Hoffmann-La Roche Ag 4-aminopyrimidin-5-yl-methanone derivatives for inhibition of cdk4 activity
WO2004074283A1 (en) * 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
WO2004100946A1 (en) * 2003-05-06 2004-11-25 Aventis Pharmaceuticals Inc. 1- (2h-pyrazol -3-yl) -3yl) {4-`1- (benzoyl) -piperidin-4-ylmethyl!-phenyl}-urea derivatives and related compounds as inhbitors of p38 kinase and/or tnf inhibitors for the treatment of imflammations
WO2005011686A1 (en) * 2003-07-28 2005-02-10 Applied Research Systems Ars Holding N.V. 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors
WO2006052189A1 (en) * 2004-11-11 2006-05-18 Astrazeneca Ab Nitro indazole derivatives

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187001A1 (en) * 1997-03-19 2003-10-02 David Calderwood 4-aminopyrrolopyrimidines as kinase inhibitors
WO2002000649A1 (en) * 2000-06-28 2002-01-03 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
WO2003022852A2 (en) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US20040097531A1 (en) * 2002-07-09 2004-05-20 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
WO2004069139A2 (en) * 2003-02-10 2004-08-19 F.Hoffmann-La Roche Ag 4-aminopyrimidin-5-yl-methanone derivatives for inhibition of cdk4 activity
WO2004074283A1 (en) * 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
WO2004100946A1 (en) * 2003-05-06 2004-11-25 Aventis Pharmaceuticals Inc. 1- (2h-pyrazol -3-yl) -3yl) {4-`1- (benzoyl) -piperidin-4-ylmethyl!-phenyl}-urea derivatives and related compounds as inhbitors of p38 kinase and/or tnf inhibitors for the treatment of imflammations
WO2005011686A1 (en) * 2003-07-28 2005-02-10 Applied Research Systems Ars Holding N.V. 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors
WO2006052189A1 (en) * 2004-11-11 2006-05-18 Astrazeneca Ab Nitro indazole derivatives

Also Published As

Publication number Publication date
WO2007113005A2 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
WO2007115805A3 (en) Aurora kinase inhibitors
WO2007123892A3 (en) Raf inhibitors and their uses
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2007098507A3 (en) Compositions and methods for inhibition of the jak pathway
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MX2009011951A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
WO2008049123A3 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
MX2010009207A (en) Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors.
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
WO2008070016A3 (en) Inhibitors of akt activity
WO2006135627A3 (en) Inhibitors of akt activity
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
EA200970447A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2008118391A3 (en) Triazinone and diazinone derivatives useful as hsp90 inhibitors
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
MX2009011950A (en) Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors.
WO2006091395A3 (en) Inhibitors of akt activity
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2006135604A3 (en) Inhibitors of checkpoint kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723952

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07723952

Country of ref document: EP

Kind code of ref document: A2